{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:20:02Z","timestamp":1785799202416,"version":"3.56.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>According to a questionnaire sent to Designated Cancer Care Hospitals in Japan in 2013, only 39.4% of the institutes had medical oncology departments. Furthermore, most of these medical oncology departments were primarily responsible for the treatment of limited disease categories and the administration of newly developed therapeutic modalities, including molecular-targeted therapy. The aim of the present study was to update these previous findings and to clarify the changes over the intervening 7-year period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The questionnaire was sent to all 393 Designated Cancer Care Hospitals on 13 March 2020. Similar to the previous questionnaires, questions were asked regarding the presence of a medical oncology department, the number of physicians in the department and the degrees of responsibility for drug therapies provided by medical oncologists to adult patients with solid cancers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 270 institutions (68.7%) responded. Overall, 145 of these 270 institutions (53.7%) had medical oncology departments, representing a significant increase compared with the results of the previous study (P\u00a0&amp;lt;\u00a00.01). Among the institutions with a medical oncology department, these departments were responsible for the administration of over 30% of all cytotoxic and molecular-targeted drug therapies for extragonadal germ cell tumors, cancers of unknown primary site, soft tissues, head and neck, esophagus, stomach, colon and rectum, and pancreas as well as the administration of immune checkpoint inhibitors (ICI) for microsatellite instability-high tumors, cancers of the stomach, esophagus and head and neck, and melanoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The proportion of institutes with medical oncology departments in Japan has increased. In addition, the responsibility of medical oncology departments has expanded to include newly emerging drugs, such as ICIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyab135","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T11:18:57Z","timestamp":1627903137000},"page":"1622-1627","source":"Crossref","is-referenced-by-count":7,"title":["Current status of medical oncology in Japan and changes over the most recent 7-year period: results of a questionnaire sent to designated cancer care hospitals"],"prefix":"10.1093","volume":"51","author":[{"given":"Makoto","family":"Arai","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan"},{"name":"Department of Gastroenterology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng Meng","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Tawada","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan"},{"name":"Chiba Prefectural University of Health Sciences, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Ishioka","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"2021110109450142400_ref1","author":"Vital Statistics Japan (Ministry of Health, Labour and Welfare)"},{"key":"2021110109450142400_ref2","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021110109450142400_ref3","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S1470-2045(15)00080-7","article-title":"Polypharmacy in patients with advanced cancer and the role of medication discontinuation","volume":"16","author":"LeBlanc","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021110109450142400_ref4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(11)70040-7","article-title":"Polypharmacy in elderly patients with cancer: clinical implications and management","volume":"12","author":"Lees","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021110109450142400_ref5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1349-7006.2012.02254.x","article-title":"Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data","volume":"103","author":"Tabuchi","year":"2012","journal-title":"Cancer Sci"},{"key":"2021110109450142400_ref6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/CCM.0000000000004087","article-title":"Critical care management of toxicities associated with targeted agents and immunotherapies for cancer","volume":"48","author":"Gutierrez","year":"2020","journal-title":"Crit Care Med"},{"key":"2021110109450142400_ref7","first-page":"81","article-title":"Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine","volume":"17","author":"Aftimos","year":"2014","journal-title":"Discov Med"},{"key":"2021110109450142400_ref8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2021110109450142400_ref9","author":"Basic plan to promote cancer control programs by Ministry of Health, Labor and Welfare (Japan)"},{"key":"2021110109450142400_ref10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/jjco\/hyu059","article-title":"Current status of medical oncology in Japan-reality gleaned from a questionnaire sent to designated cancer care hospitals","volume":"44","author":"Takiguchi","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"2021110109450142400_ref11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.4143\/crt.2016.313","article-title":"Survey of medical oncology status in Korea (SOMOS-K): a national survey of medical oncologists in the Korean association for clinical oncology (KACO)","volume":"49","author":"Kim","year":"2017","journal-title":"Cancer Res Treat"},{"key":"2021110109450142400_ref12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/annonc\/mdt522","article-title":"The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)","volume":"25","author":"Popescu","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/11\/1622\/41029461\/hyab135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/11\/1622\/41029461\/hyab135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T09:45:17Z","timestamp":1635759917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/11\/1622\/6355135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":12,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,20]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyab135","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,8,20]]}}}